TCF7L2 Antibody - BSA Free

Western Blot: TCF7L2 Antibody [NBP1-19083] - Western blot analysis of TCF7L2 (F) protein in D3H2LN TNBC cells after treatment with SCR or SID decoy peptide (2.5uM, 24 hours). SID decoy treatment inhibited full-length (~64 kDa) and, to a greater extent, short isoform variant (~53 kDa) TCF7L2 proteins in comparison to untreated or SCR treated controls. The band intensities for TCF7L2 in each lane were normalized to the GAPDH loading control and indicated in red. The result is representative of three independent experiments. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.11381) licensed under a CC-BY license.

Immunocytochemistry/Immunofluorescence: TCF7L2 Antibody [NBP1-19083] - TCF7L2 antibody was tested in Hela cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).

Western Blot: TCF7L2 Antibody [NBP1-19083] - Jurkat cell line.

• Reactivity: Hu, Mu, Bv
• Applications: WB, ICC/IF
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1 mg/ml

TCF7L2 Antibody - BSA Free Summary

• Description: Novus Biologicals Rabbit TCF7L2 Antibody - BSA Free (NBP1-19083) is a polyclonal antibody validated for use in WB and ICC/IF. Anti-TCF7L2 Antibody: Cited in 1 publication. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: Synthetic peptide made to an internal portion of human TCF7L2 (within residues 150-200). [Swiss-Prot# Q9NQB0]
• Predicted Species: Mouse (93%), Bovine (93%). Backed by our 100% Guarantee.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: TCF7L2
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/ Immunofluorescence 1:100
  • Western Blot 0.5 ug/ml
• Application Notes: This TCF7L2 antibody is useful for Immunocytochemistry/Immunofluorescence and Western blot, where a band is seen ~55 kDa. In ICC/IF cytoplasmic staining was observed. The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Theoretical MW: 55 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Control:

  Jurkat Whole Cell Lysate
  TCF7L2 Overexpression Lysate

• Control Peptide:

  TCF7L2 Peptide (NBP1-19083PEP)

Reactivity Notes

Immunogen displays the following percentage of sequence identity for non-tested species: mouse (93%) and bovine (93%).

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.02% Sodium Azide
• Concentration: 1 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for TCF7L2 Antibody - BSA Free

• HMG box transcription factor 4
• hTCF-4
• T-cell factor 4
• T-cell factor-4 variant A
• T-cell factor-4 variant B
• T-cell factor-4 variant C
• T-cell factor-4 variant D
• T-cell factor-4 variant E
• T-cell factor-4 variant H
• T-cell factor-4 variant I
• T-cell factor-4 variant J
• T-cell factor-4 variant K
• T-cell factor-4 variant L
• T-cell factor-4 variant M
• T-cell factor-4 variant X2
• T-cell-specific transcription factor 4
• TCF-4T-cell factor-4 variant F
• TCF4T-cell factor-4 variant G
• transcription factor 7-like 2 (T-cell specific, HMG-box)
• transcription factor 7-like 2

Background

TCF7L2 (transcription factor 7-like 2, also called TCF4) is a key component in WNT signal transduction pathway which is implicated in several fundamental cellular processes such as embryonic development, stem cell maintenance, cellular fate, proliferation, survival, migration, tumour suppression, and oncogenesis. TCF7L2 gene codes for HMG- box transcription factor and through its critical role in WNT/beta-catenin signaling, it plays important role in cellular development as well as growth regulation. TCF7L2 participates in the process of blood glucose homeostasis via its regulatory effects on GLP-1 (glucagon-like peptide 1) and gene variants rs12255372 as well as rs7903146 have been documented to be associated with risk for NIDDM/Type 2 diabetes. TCF7L2 also regulates the transcription of proglucagon gene in enteroendocrine cells and has been suggested to be implicated in obesity also. TCF7L2 has been shown associate with human carcinogenesis specifically with triple negative i.e. ER, PR, HER2 negative or basal-like breast cancers.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for TCF7L2 Antibody (NBP1-19083)(1)

Publication using NBP1-19083

• Kwon YJ, Leibovitch BA, Bansal N et al. Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells Oncotarget. 2017-10-24 [PMID: 29179446] (ICC/IF, Human)

Bioinformatics

• Gene Symbol: TCF7L2